Search

Displaying results 3161 - 3170 of 4437 in total
  1. Drug

    SR-123781A

    go.drugbank.com/drugs/DB05361
    Investigational

    It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).

  2. Drug

    BMS-986251

    go.drugbank.com/drugs/DB19007
    Investigational

    BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

  3. Drug

    Nezastomig

    go.drugbank.com/drugs/DB19061
    Investigational

    Nezastomig is under investigation in clinical trial NCT06085664 (A Pilot Presurgical Trial of REGN5678 (Anti-psma X CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

  4. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  5. Drug

    Magnesium gluconate

    go.drugbank.com/drugs/DB13749
    ApprovedWithdrawn

    Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many fo...

  6. Drug

    Phenoxybenzamine

    go.drugbank.com/drugs/DB00925
    ApprovedInvestigational

    An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.

  7. Drug

    Amylocaine

    go.drugbank.com/drugs/DB09088
    ApprovedWithdrawn

    Finally, in 1903 the world's first synthetic and non-addictive local anesthetic, amylocaine, was synthesized and patented under the name Forneaucaine by Ernest Fourneau at the Pasteur Institute [L1882]

  8. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  9. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]

  10. Drug

    Inetetamab

    go.drugbank.com/drugs/DB17457
    Investigational

    It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.